Investors sold shares of Amgen Inc. (NASDAQ:AMGN) on strength during trading on Monday. $146.53 million flowed into the stock on the tick-up and $196.22 million flowed out of the stock on the tick-down, for a money net flow of $49.69 million out of the stock. Of all equities tracked, Amgen had the 0th highest net out-flow for the day. Amgen traded up $5.85 for the day and closed at $186.49
Several analysts recently commented on the company. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $203.00 target price on shares of Amgen in a report on Thursday, September 7th. Cann reiterated a “buy” rating on shares of Amgen in a report on Monday, August 28th. Mizuho reiterated a “buy” rating and issued a $183.00 target price (down from $195.00) on shares of Amgen in a report on Monday, August 21st. BidaskClub cut Amgen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Finally, Argus upped their target price on Amgen from $180.00 to $195.00 and gave the company a “buy” rating in a report on Thursday, July 27th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. Amgen currently has a consensus rating of “Buy” and a consensus target price of $186.04.
The stock has a market cap of $139.37 billion, a P/E ratio of 17.40 and a beta of 1.35. The stock has a 50-day moving average price of $173.95 and a 200 day moving average price of $168.82.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same period in the previous year, the company posted $2.84 earnings per share. The firm’s revenue was up 2.1% on a year-over-year basis. On average, equities analysts predict that Amgen Inc. will post $12.57 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were given a dividend of $1.15 per share. The ex-dividend date was Tuesday, August 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.41%. Amgen’s dividend payout ratio is presently 41.93%.
Institutional investors have recently added to or reduced their stakes in the business. TrimTabs Asset Management LLC boosted its holdings in Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after acquiring an additional 288 shares in the last quarter. Alpha Omega Wealth Management LLC boosted its holdings in Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after acquiring an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. boosted its holdings in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after acquiring an additional 4 shares in the last quarter. American Beacon Advisors Inc. bought a new stake in Amgen in the first quarter worth $106,000. Finally, Phocas Financial Corp. bought a new stake in Amgen in the second quarter worth $110,000. 78.14% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This story was published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.themarketsdaily.com/2017/09/13/investors-sell-shares-of-amgen-inc-amgn-on-strength-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.